1,123 Shares in STERIS plc (NYSE:STE) Acquired by Aristides Capital LLC

Aristides Capital LLC bought a new stake in shares of STERIS plc (NYSE:STE) during the 1st quarter, HoldingsChannel reports. The institutional investor bought 1,123 shares of the medical equipment provider’s stock, valued at approximately $252,000.

Several other hedge funds also recently bought and sold shares of the business. Global Retirement Partners LLC lifted its position in STERIS by 9.4% during the first quarter. Global Retirement Partners LLC now owns 570 shares of the medical equipment provider’s stock worth $128,000 after buying an additional 49 shares in the last quarter. First Hawaiian Bank grew its holdings in shares of STERIS by 0.4% in the 1st quarter. First Hawaiian Bank now owns 13,857 shares of the medical equipment provider’s stock worth $3,115,000 after acquiring an additional 50 shares during the period. UMB Bank n.a. lifted its stake in STERIS by 7.8% in the 4th quarter. UMB Bank n.a. now owns 716 shares of the medical equipment provider’s stock valued at $157,000 after buying an additional 52 shares in the last quarter. Kentucky Retirement Systems Insurance Trust Fund lifted its stake in shares of STERIS by 1.5% during the 4th quarter. Kentucky Retirement Systems Insurance Trust Fund now owns 3,520 shares of the medical equipment provider’s stock worth $774,000 after purchasing an additional 53 shares during the period. Finally, J.Safra Asset Management Corp lifted its stake in shares of STERIS by 77.9% during the 1st quarter. J.Safra Asset Management Corp now owns 121 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 53 shares during the period. Institutional investors own 94.69% of the company’s stock.

STERIS Price Performance

NYSE:STE traded up $5.23 during mid-day trading on Friday, hitting $232.79. The company’s stock had a trading volume of 329,376 shares, compared to its average volume of 405,734. The company has a market capitalization of $23.01 billion, a price-to-earnings ratio of 60.94 and a beta of 0.83. The stock has a fifty day moving average of $223.23 and a 200-day moving average of $221.85. The company has a current ratio of 3.08, a quick ratio of 2.36 and a debt-to-equity ratio of 0.49. STERIS plc has a fifty-two week low of $195.47 and a fifty-two week high of $254.00.

STERIS (NYSE:STE) last announced its quarterly earnings results on Wednesday, May 8th. The medical equipment provider reported $2.58 earnings per share for the quarter, topping analysts’ consensus estimates of $2.41 by $0.17. STERIS had a net margin of 6.95% and a return on equity of 13.73%. The company had revenue of $1.42 billion for the quarter, compared to analysts’ expectations of $1.41 billion. During the same period last year, the firm posted $2.30 earnings per share. The business’s quarterly revenue was up 10.8% compared to the same quarter last year. As a group, equities analysts forecast that STERIS plc will post 9.25 EPS for the current fiscal year.

STERIS Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, June 26th. Investors of record on Wednesday, June 12th were issued a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a dividend yield of 0.89%. The ex-dividend date was Wednesday, June 12th. STERIS’s payout ratio is 54.45%.

Analysts Set New Price Targets

STE has been the topic of a number of recent research reports. Needham & Company LLC restated a “hold” rating on shares of STERIS in a research note on Friday, May 10th. StockNews.com raised STERIS from a “hold” rating to a “buy” rating in a report on Saturday, June 15th. JMP Securities reaffirmed a “market outperform” rating and set a $265.00 target price on shares of STERIS in a report on Friday. Finally, Piper Sandler reaffirmed a “neutral” rating and set a $225.00 target price (up from $220.00) on shares of STERIS in a report on Friday, May 10th. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, STERIS presently has an average rating of “Moderate Buy” and a consensus target price of $241.60.

Insider Buying and Selling

In other news, Director Jacqueline B. Kosecoff sold 4,584 shares of the business’s stock in a transaction that occurred on Monday, May 13th. The shares were sold at an average price of $231.53, for a total value of $1,061,333.52. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, Director Jacqueline B. Kosecoff sold 4,584 shares of the stock in a transaction on Monday, May 13th. The shares were sold at an average price of $231.53, for a total transaction of $1,061,333.52. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, SVP Cary L. Majors sold 2,024 shares of the company’s stock in a transaction on Monday, May 13th. The stock was sold at an average price of $232.13, for a total transaction of $469,831.12. Following the transaction, the senior vice president now owns 11,369 shares in the company, valued at approximately $2,639,085.97. The disclosure for this sale can be found here. In the last 90 days, insiders sold 7,762 shares of company stock valued at $1,798,477. Company insiders own 1.14% of the company’s stock.

STERIS Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.